Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status approved
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 73289-0063; 73289-0064; 14445-012; 66651-914; 16714-549; 27808-246; 0131-5410; 47335-918; 50228-193; 51407-721; 51991-348; 51991-349; 60687-698; 65162-923; 65162-926; 68083-480; 68462-680; 69539-026; 72865-235; 36998-1810; 0904-7244; 65977-0075; 14445-132; 31722-627; 31722-814; 31722-815; 0131-2479; 42291-862; 47335-980; 53746-925; 66689-108; 69543-455; 70710-1886; 0904-7246; 0904-7247; 65372-1186; 0131-2478; 47335-922; 53746-926; 60687-676; 65862-749; 66689-109; 67877-736; 68462-678; 68462-681; 62332-173; 65862-747; 12828-0087; 14445-021; 42765-060; 65862-720; 68225-057; 14445-129; 14445-130; 31722-813; 60505-0405; 62332-171; 65219-204; 65862-748; 69367-350; 72603-140; 13612-0021; 0904-7245; 50370-0024; 66039-882; 27808-244; 31722-812; 0131-1810; 46708-171; 47335-943; 50228-192; 62332-172; 62332-174; 69367-348; 70771-1682; 36998-2478; 16714-552; 27808-245; 0131-2480; 42291-860; 42934-303; 46708-172; 46708-173; 51407-722; 51991-351; 60687-687; 67877-733; 67877-735; 69367-351; 69539-025; 70954-488; 36998-0119; 36998-2480; 52038-005; 53747-069; 62331-062; 16714-548; 25021-791; 31722-203; 0121-1012; 0121-2024; 46708-174; 51991-350; 65162-924; 65162-925; 66689-107; 67877-734; 69539-027; 72205-220; 72266-242; 16436-0101; 17180-2746; 36998-2477; 36998-2479; 16714-550; 53746-924; 65862-750; 66689-110; 69539-028; 73289-0065; 17205-107; 0131-2477; 42291-861; 42291-863; 50228-194; 51407-723; 51407-724; 53746-923; 68462-679; 69367-349; 70710-1359; 14445-131; 14445-406; 27808-243; 50228-195
UNII 563KS2PQY5
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neonatal respiratory distress syndrome18.04.10.003; 22.11.02.0100.001463%-
Panniculitis lobular23.07.02.0050.001463%-
Persecutory delusion19.10.01.0070.001463%-
Pulmonary artery stenosis22.06.03.006; 24.04.09.0110.001463%-
Toxic optic neuropathy06.02.08.003; 12.03.01.033; 17.04.05.0090.002194%-
Hypothermia neonatal08.05.01.007; 12.05.03.002; 18.04.06.0040.001463%-
Breast cancer metastatic16.10.01.008; 21.05.01.0160.001463%-
Cell death08.03.03.003; 14.11.02.0050.001463%-
Sopor17.02.04.021; 19.02.04.0020.003657%-
Psychogenic seizure17.12.03.042; 19.24.01.0070.003949%-
Sputum retention22.02.03.0120.001463%-
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.002194%-
Encephalitis autoimmune10.04.10.012; 16.32.01.006; 17.06.05.0020.001463%-
Change in seizure presentation17.12.03.0220.002194%-
Disorganised speech17.02.08.017; 19.19.02.0050.001463%-
Tongue discomfort07.14.02.0190.003218%-
Behaviour disorder19.01.01.0050.010385%-
Drug effective for unapproved indication08.06.01.037; 12.09.02.0010.004973%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.016820%-
Focal dyscognitive seizures17.12.02.0050.004680%-
Hepatic cytolysis09.01.07.0360.002194%-
Immobilisation syndrome08.01.03.092; 15.03.05.0170.001463%-
Intermenstrual bleeding21.01.01.0150.005704%-
Juvenile myoclonic epilepsy17.12.03.0370.001463%-
Neonatal cardiac failure02.05.01.015; 18.04.07.0130.001463%-
Skin laceration12.01.06.016; 23.03.11.041---
Suspected suicide08.04.01.017; 19.12.01.0090.001463%-
Therapeutic product ineffective08.06.01.0570.001463%-
Therapeutic response changed08.06.01.0590.002194%-
Treatment noncompliance08.06.01.067; 12.09.02.0060.016674%-
The 10th Page    First    Pre   10    Total 10 Pages